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Abstract
Uridine-disphosphate glucuronosyl transferase (UGT) enzymes catalyze the formation of
glucuronide conjugates of Phase II metabolism. Methods for absolute quantification of UGT1A1
and UGT1A6 were previously established utilizing stable isotope peptide internal standards with
LC-MS/MS. The current method expands upon this by quantifying eight UGT1A isoforms by
nanobore HPLC coupled with a linear ion trap-time of flight mass spectrometer platform.
Recombinant enzyme digests of each of the isoforms were used to determine assay linearity and
detection limits. Enzyme expression level in human liver, kidney and intestinal microsomal
protein was determined by extrapolation from spiked stable isotope standards. Intraday and
Interday variability was <25% for each of the enzyme isoforms. Enzyme expression varied from 3
pmol/mg protein to 96 pmol/mg protein in liver and intestinal microsomal protein digests.
Expression levels of UGT1A7, 1A8 and 1A10 were below detection limits (<1 pmol/mg protein)
in HLMs. In kidney microsomes the expression of UGT1A3 was below detection limits, but levels
of UGT1A4, 1A7, 1A9 and 1A10 protein were higher relative to liver, suggesting that renal
glucuronidation could be a significant factor in renal elimination of glucuronide conjugates. This
novel method allows quantification of all nine UGT1A isoforms, many previously not amenable to
measurement with traditional methods such as immunologically based assays. Quantitative
measurement of proteins involved in drug disposition, such as the UGTs, significantly improves
the ability to evaluate and interpret in vitro and in vivo studies in drug development.
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UGT enzymes catalyze the formation of glucuronide conjugates of Phase II metabolism.
Through the actions of the cofactor uridine-disphosphate glucuronide acid (UDPGa) and
UGT enzymes, glucuronidation encompasses the most common and clinically important of
the Phase II metabolic pathways1 . Large numbers of endogenous and exogenous
compounds are converted to more hydrophilic conjugates, which are eliminated by
excretion. In humans, the UGT genome consists of two families and three subfamilies. The
UGT1A locus is found on chromosome 2q37 and encodes for nine functional enzymes
located throughout the body2 . Traditional quantification methods that have been used to
evaluate relative UGT levels include Western blots, ELISAs and RT-PCR studies, but these
methods lack the sensitivity, reproducibility and dynamic range to examine expression in
liver tissues. Using RT-PCR the correlation between mRNA levels measured and protein
expression is often poor, making this method unreliable for evaluation of expression in
biological systems3 . In addition, the high degree of sequence homology between UGT
enzymes (as high as 94% in some isoforms) prevents the raising of antibodies against
specific UGT isoforms, with few exceptions1,4 .
Other traditional approaches to relative protein quantification include differential gel
electrophoresis (DIGE) which involves separation through 2D-gel electrophoresis followed
by fluorescent tagging of lysine side chains5. While multiple proteins may be monitored
through the DIGE technique using alternate fluorescent tags, it is often difficult to
distinguish high and low molecular weight proteins, and DIGE often lacks the sensitivity to
detect low abundant proteins6. In recent years, advances in electrospray ionization (ESI),
coupled with sensitive tandem mass spectrometry (MS/MS), has allowed for the
development of several approaches to relative protein quantification. Methods measuring
proteins within cells include in vivo metabolic labeling in enriched media (C13, N15, O18),
followed by digestion and quantification of labeled peptides to evaluate changing expression
of proteins of interest7-10. These methods have been used to determine expression changes
in myoglobins, immune response, HIV levels, glycoproteins and mitochondrial proteins.
Recently, label-free techniques have also been used that can evaluate global expression
changes, but these methods are not commonly employed for targeted protein quantification
due to variability across instrumentation platforms and ion suppression from complex
matrices5.
Along with the use of capillary LC-MS/MS for relative quantification for global proteomics,
stable isotope internal standards also have been employed for targeted absolute quantitative
proteomics. Labeling techniques such as ICAT and iTRAQ can be utilized for relative
quantification or for absolute quantification if a known amount of labeled targeted peptide is
added during sample preparation11-14. However, because ICAT reagents only target peptides
with cysteine groups, the number of potential targeted peptides is limited6. Furthermore, the
selection of precursor ions in complex matrices can be difficult using iTRAQ methods6.
Although both ICAT and iTRAQ methods have greatly increased sensitivity and selectivity
of peptide/protein analysis, when compared with gel based methods, other more general
approaches are being developed6,14.
In recent years stable isotope labeled peptides as internal standards have successfully been
used for the absolute quantification of proteins and peptides. Barr et al. 15 were able to
accurately quantify apolipoprotein A-1 using unique heavy-labeled peptides. Following
these initial experiments, both C-reactive protein (CRP) and prostate specific antigen (PSA)
were quantified within human plasma by preselecting heavy isotope-labeled peptide internal
standards added prior to a tryptic protein digestion16,17. Using sensitive capillary LC
coupled to MS/MS, it was found that the concentrations of PSA and CRP measured were
Harbourt et al. Page 2













comparable to those determined by immunoassay, with lower detection limits16,17. These
methods fostered the development of stable isotope labeling with amino acids in cell culture
(SILAC), and absolute quantification (AQUA) and Quantitative Concatamer (QCAT) stable
isotope standards, and have been applied more recently for determining gonadotropin
releasing hormone (GnRH)18. While QCAT standards require development of recombinant
protein expression in cell lines to produce heavy labeled internal standard proteins for
quantification, heavy isotope-labeled peptides can be readily prepared following
preselection using standard peptide synthesis techniques.
While LC connected to triple quadrupole tandem MS has been used for MRM
quantification, other mass spectrometry platforms have also been successfully implemented
for these purposes. LC-MS/MS has been applied using quadrupole time of flight (Q-TOF)
mass spectrometry for both metabolite detection and peptide quantification19, 20. In addition,
a new MS platform that couples capillary (nano)LC to a linear ion trap time of flight (LIT-
TOF) mass spectrometer from Hitachi High-Technologies has been utilized for both
qualitative and quantitative mass spectrometry21-24. Recently, Ito et al.24 were able to
successfully quantify a novel glycosylated phospholipid and demonstrate that the LIT-TOF
platform was not only very sensitive, but also has a dynamic range approaching three orders
of magnitude.
We have previously demonstrated the utility of quantifying UGTs using stable isotope
standards and tandem LC-MS25. While this method was successfully applied for
quantification of two of the nine active human UGT isoforms, it has been necessary to
extend the method for the remaining UGT1A isoforms to not only better examine the
relationship within and across species, but also, in a single chromatographic run, to be able
to quantify other UGT1A isoforms that lack specific antibodies. By taking advantage of the
increased sensitivity offered by nanoLC compared to standard bore HPLC and by extending
the LC gradient for better separation of peptides, we demonstrate here the ability to
selectively quantify eight of the nine active UGT1As (recombinant UGT1A5 was
unavailable for this work) in a single chromatographic run. Here we present our method




Analytical grade acetonitrile and methyl alcohol (anhydrous) were purchased from Fisher
Scientific Co. (Pittsburg, PA). Ammonium bicarbonate, dithiothreitol, iodoacetamide,
ammonium hydroxide, formic acid and TPCK (L-1-tosylamido-2-phenylethyl chloromethyl
ketone) treated trypsin from bovine pancreas (≥ 10,000 BAEE units/mg protein) were
purchased from Sigma-Aldrich Co. (St. Louis, MO). Bond Elut solid phase extraction (SPE)
cartridges (C18 100mg, 1mL) were purchased from Varian, Inc. Recombinant UGTs 1A1,
1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10 and control supersomes were purchased from BD
Biosciences (San Jose, CA). Human liver microsomes (HLMs) (20 mg/mL) were purchased
from BD Biosciences (pool of 33; 15 female, 18 male) and Xenotech LLC (Lenexa, KA)
(pool of 50; 26 female, 24 male). A human liver microsome library of individual donors
(n=9, 3 female, 6 male, 20 mg/mL) was purchased from Human Biologics International
(Scottsdale, AZ). Human kidney microsomes were purchased from BD Biosciences (pool of
33, 14 Female, 19 Male, 20 mg/mL) and pooled human intestinal microsomes (HIMs) were
obtained from Xenotech LLC (Lenexa, KA) (8 donors, 5 Female, 3 Male). Human intestinal
microsome samples from individual donors (n=3, 1 Female, 2 Male) was graciously donated
by Dr. Mary Paine (UNC-Chapel Hill, Chapel Hill, NC)26. Protein concentrations were
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determined using the Pierce BCA Protein Assay Kit, in which bovine serum albumin is used
as the standard.
Instrumentation
Samples were analyzed using nanoLC (NanoFrontier L series; Hitachi High-Technologies,
Tokyo, Japan) attached to a LIT-TOF mass spectrometer (Hitachi High-Technologies,
Tokyo, Japan). The nanoLC was coupled to an AT10PV nano-flow gradient generator and
connected to the LIT-TOF instrument with an electrospray ion source24, 27 . The LC column
was a monolithic C-18 column (GL Sciences, Tokyo, Japan, 150 mm, 0.075 mm ID). The
instrument was operated in positive ion mode for MRM analysis. Data analysis was
performed using NanoFrontier LD-ECD Data Processing software (Hitachi High-
Technologies, Tokyo, Japan).
Stable isotope labeled internal standards
Synthetic peptide standards (most were 8-14 mer; Table 1), each containing one amino acid
heavy labeled with 13C [98 %] and 15N [95 %], were purchased from Thermo Electron
(Thermo Scientific, Waltham, MA) using previously reported selection criteria, including
manufacturer recommendations7, 25, 28. For each UGT isoform, two unique peptides were
purchased for analysis and validation. Amino acid sequences for the nine active human
UGT1A isoforms (including for UGT1A5, which was unavailable in recombinant form)
were obtained using the Universal Protein Resource Knowledge Base (UniProtKB). Peptide
uniqueness of tryptic fragments was verified by NCBI Blast (National Center for
Biotechnology Information Basic Local Alignment Search Tool). Amino acid analysis on
each peptide to determine sample purity was conducted as previously described25. Known
variable single nucleotide polymorphisms (SNPs) were also considered during peptide
selection. While at the time of purchase there were no known interferences with SNPs along
the targeted protein sequence, reports indicate that there are potential conflicts due to
polymorphisms for UGT1A1 (Peptide 2, frequency <1 %), and UGT1A6 (Peptide 4,
frequency ~4 % in Caucasians)29-31. Furthermore, while it was initially intended to obtain
two unique peptides per isoform, the dearth of unique peptides for UGT1A7, UGT1A8 and
UGT1A9 that are amendable to the LC-MS approach only provided one unique peptide for
these isoforms along with one peptide that is shared between the two isoforms. Upon
application, several selected peptides failed to provide useful data for quantitative
measurement, thus UGT1A3, UGT1A4 and UGT1A10 were also only measured based on
one heavy labeled peptide. The high sequence homology of the UGTs and exon sharing with
identical C-terminus for the UGT1As made peptide selection challenging.
Sample preparation
Aliquots of 50 μg of microsomal protein, recombinant enzyme or UGT control supersomes
were denatured and digested as previously reported with some modifications25. Samples
were denatured and reduced by heating at 95 °C for 10 min in 5 mM dithiothreitol (sample
volume 90 μL; buffer 50 mM ammonium bicarbonate). This was followed by alkylation
with 100 mM iodoacetamide stock for 20 min in the dark. Heavy labeled peptides were then
added as internal standards (10 pmol for each peptide, excluding peptides 16 and 17 for
which signal intensities were too low; Table 1) and the residual acetonitrile (<5 μL) was
removed by evaporation under nitrogen for ~5 min. Samples were then digested with trypsin
in 50 mM ammonium bicarbonate; enzyme/protein ratio = 1:50; for 4 h at 37 °C (sample
volume was brought to 150 μL by addition of HPLC water). The reaction was quenched by
addition of 50 μL acetonitrile. Following centrifugation at 1000g for 10 min, the organic
content was removed by evaporation under nitrogen for ~10 min. An aliquot of 0.9 mL of 50
mM ammonium bicarbonate was then added in preparation for solid phase extraction. SPE
cartridges were conditioned with methanol and distilled water. Samples were added and the
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cartridges were washed with 1 mL 10 mM ammonium acetate (pH 3). Samples were then
eluted with acetonitrile/25 mM formic acid (40:60). The eluate was evaporated to dryness
under nitrogen at 42°C in a water bath, and samples were reconstituted with 250 μL (80:20)
acetonitrile/25 mM formic acid at pH 3 (pH was adjusted to 3 by drop wise addition of
ammonium hydroxide), a high volume to minimize sample loss on glass tubes. Following
initial reconstitution, samples were transferred to injection vials and dried again under
nitrogen at 42 °C. They were then reconstituted in 50 μL (15:85) acetonitrile/25 mM formic
acid at pH 3. Samples were stored at −20 °C until analyzed by nanoLC-MS/MS.
MRM selection
All peptide heavy labeled standards were directly infused into the LIT-TOF mass
spectrometer at a rate of 2 μL/min for MRM optimization. Upon infusion, most peptide
standards were doubly charged. Peptides 5, 16 and 17, were found to be triply charged or
greater and were ultimately excluded because of inadequate MRM selection (Table 1). For
each peptide, two MRMs above 500 m/z were selected for use in quantification (Figure 1).
MRM selections were confirmed on the LIT-TOF following optimization of the nanoLC
gradient using a solution containing 10 pmol of each peptide.
NanoLC-MS/MS conditions
The mobile phase consisted of 25 mM formic acid in water (solvent A) and acetonitrile
(solvent B). A 1 μL injection (approximately 1 μg of digested protein) was loaded onto a 5
cm trap column (C18, 2.1 mm ID, 5 μm particle size) at a rate of 10 μL/min for 4 min. The
sample was then transferred onto the analytical column and analyzed under the following
linear gradient conditions, 0 min, 5 % B; 30 min, 55 % B; 30.1 min, 100 % B; 40 min, 100
% B; 40.1 min, 5 % B and then equilibrated until 65 min. The gradient pump maintained a
100 μL/min flow rate while the nanoflow pump was run at 200 nL/min during analysis. MS
conditions were similar to those previously reported by Ito et al24 except the AP1
temperature was set to 120 °C, with an isolation time of 50 ms.
Calibration curves
Recombinant enzymes of all UGT1A isoforms, excluding UGT1A5 (not commercially
available in recombinant form), were used to establish recombinant enzyme calibration
curves that demonstrated linearity. Tryptic digestion volumes were maintained by dilution
with tris buffer at pH 7.4. Prior to the digestion, 10 pmol of each heavy labeled peptide
standard was added and the response ratio between the labeled and unlabeled peptides was
used to establish a calibration curve and to verify linearity. Equality of response between the
labeled and unlabeled peptides along with complete tryptic digestion was assumed in the
creation of the calibration curves. Calibration curves were constructed using peak area ratios
of unlabeled to labeled for each MRM selected. Enzyme concentrations, in units of pmol/mg
(microsomal) protein, were extrapolated from the curves for unknown samples.
Inter- and intraday assay variability
To examine intraday variability, five replicate calibration curves for human liver, intestinal
and kidney microsomes were prepared and analyzed on the same day. Where available,
measurements for two peptides per UGT1A isoform were averaged to obtain final enzyme
expression levels. Interday variability experiments were carried out in a similar manner with
standard curves being prepared and analyzed on five different days for digests of human
liver and intestinal microsomes.
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Human liver and intestinal microsomal library
To compare the newly established method to our initial method25 samples from a library of
nine individual liver microsomal donors were analyzed in duplicate. Intestinal microsomes
from three individual donors were also analyzed in duplicate. For the human liver
microsomal library, enzyme expression levels of UGT1A1 and UGT1A6 were compared to
results obtained using the previous assay25.
Results and Discussion
MRM Scheduling
Following initial tests on the instrumentation, it was found that peptides of interest eluted
between 17 and 32 min. Further increases in the % B at the beginning of the nanoLC
gradient or increases in slope of the gradient to decrease run times resulted in band
broadening or loss of signal. Peptides eluted consistently within five separate time windows
(T2 – T6) (T1 0-17 min, T2 17-19.5 min, T3 19.5-22.0 min, T4 22.1-26.4 min and T5 26.5-28
min, T6 28.1-32 min) and MRM scheduling was optimized with the NanoFrontier LD-ECD
software. Selected MRM extractions from a representative single chromatographic run are
shown in Figure 2. MRMs for peptides 5, 14, 16 and 17 were not consistently detectable,
and were excluded from sample analysis.
Calibration curves
One calibration curve was constructed for each MRM, two per peptide when available,
resulting in a maximum of six curves per UGT isoform (three peptides were used for
UGT1A6). Concentrations for each isoform, in units of pmol/mg protein, were expressed as
an average of concentrations determined from all curves. Calibration curves produced a
linear range (Figure S-1) for recombinant microsomal protein with an LOD of
approximately one third of the lowest concentration on the calibration curves (the lowest
concentration on the curves was ~1 pmol enzyme/mg protein). Calibration curves were
similar between MRMs for each peptide. Peptides that did not generate quality product ion
scans, stable and reproducible LC retention times, sufficient sensitivity and precise
quantification (% C.V. <25 % with repeat sampling) were excluded from all UGT enzymatic
analyses. All R2 values for calibration curves were between 0.96 and 0.99.
Intraday and interday variability
Intraday variability measurements (n=5) for the UGTs provided reproducible results with
minimal variation (<25 %) between samples. UGT1A1 enzyme levels were 22.7 pmol/mg
protein in human liver microsomes (Table S-1) which is similar to what we reported
earlier15. UGT1A6 levels were 8.5 pmol/mg protein in the same matrix (Table S-1). These
concentrations were more reproducible than those of UGT1A1 and less reproducible than
those of the other liver isoforms (Table S-1). Peptides for isoforms UGT1A7, UGT1A8 and
UGT1A10 were below detection limits in the liver, which is in agreement with previous
reports of the liver expression of these isoforms as determined by mRNA analysis1, 32, 33. In
addition, UGT1A3 and UGT1A4 were below detection limits in the intestine1, 32. In
contrast, UGT1A3 was the only isoform assayed that was below detection limits in the
kidney (1A5 was not assayed). With few exceptions, interday C.V. values were below 25 %
for each of the UGT enzymes (Table S-1). Intraday variability studies produced similar
results with regard to both variability and expression (Table S-2).
Human liver, intestine and kidney UGT expression
The data from liver microsomes indicated that UGT1A1 and UGT1A9 consistently had the
highest enzyme expression levels among the UGTs (Figure 3). While UGT1A3, UGT1A4
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and UGT1A6 were readily detectable, their expression levels (3.2 for 1A3, 7.4 for 1A4, and
8.5 pmol/mg protein for 1A6) were generally lower when compared to the other two
enzymes. UGT1A1 expression was highest in the liver along with UGT1A3 and UGT1A6
relative to the two other tissues examined. UGT1A8 was found at its highest levels within
the intestine while UGT1A7, UGT1A9 and UGT1A10 were more extensively expressed in
the kidney.
Human liver and intestinal libraries
Results of analysis of the human liver and intestinal libraries are shown in Table 2. UGT1A1
expression varied five fold (7.0 pmol/mg protein to 32.6 pmol/mg protein) in the liver
microsomes which was the general trend for variation in liver expression for the other
measurable isoforms. An exception was UGT1A9, where variation was more than ten fold in
the liver (9.0 pmol/mg protein to 96.4 pmol/mg protein in liver). Unlike the liver library, the
intestinal enzyme expression data suggested less variability between individuals though the
sample size was only three. Most isoforms demonstrated between 1.5 to 3 fold variability
between the lowest and highest concentration in intestine. While UGT1A4 was detected in
two of the three individual intestinal specimens, it was not detected in the pooled human
intestinal microsomal digests. Another exception was UGT1A8 which demonstrated five
fold variability (1.9 pmol/mg protein to 9.4 pmol/mg protein) in the intestine. Isoforms that
were determined to be below detection limits within the pooled microsomal studies,
excluding UGT1A4, were also not detected in any of the individual library specimens.
To further validate the nanoLC LIT-TOF based assay for UGT expression, UGT1A1 and
UGT1A6 enzyme rank orders and enzymatic levels were compared to the corresponding
results obtained using our previously developed assay (on the LC coupled to an ABI
3000)25. Tests for both isoforms indicated a strong Pearson correlation (r=0.926 for
UGT1A1, Figure S-2; r=0.854, Figure S-3 for UGT1A6, n=9 for each isoform) between
platforms. Furthermore, the rank orders for each isoform within the library specimens were
similar and most of the enzyme levels obtained using the current method varied <20 % from
the values determined using the previous assay25.
In recent years, the use of stable isotope internal standards with tandem MS methods to
quantify biologically active proteins has become more common25, 34,35. The goal of this
report was to develop a method that could successfully quantify all of the human UGT1A
enzymes within a single chromatographic run using nanoLC-MS/MS, the preferred platform
for many researchers in proteomics5, 18, 36. While triple quadrupole mass spectrometry has
been applied for quantification, other hybrid instruments, including the LIT-TOF used in
this study, have also been used and have displayed the selectivity and sensitivity desired to
quantify biological enzymes in complex matrices. Thus a range of MS platforms may be
successfully employed for targeted quantitative proteomics, though sensitivity may vary
between platforms.
The UGT1A protein sequence is ~530 amino acids in length and consists of five exons, of
which amino acids residing in the C terminus (exons 2-5) are shared between each 1A
isoform1. The N terminal region is subject to individual enzyme splicing, resulting in the 9
unique active isoforms and 4 pseudogenes in humans1, 2. Because of this, amino acid
sequences unique to each isoform are often a small list, making proteoytpic peptide selection
limited. It is desired in targeted quantitative proteomics to select two unique peptides per
protein and at least two MRMs per peptide over 500 m/z for optimal sensitivity and
selectivity37. In our study the limited selection window for UGT1A8 and UGT1A9 resulted
in the selection of only one unique peptide for each of these isoforms. A second peptide of
sequence TYSTSYTL*EDLDR, was found to be shared between the two isoforms.
Furthermore, peptides containing reactive/unstable amino acids such as methionine and
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cysteine, which are normally excluded based on selection criteria, were selected and
employed due to a lack of unique peptides for some UGT1A isoforms (Table 1).
Peptide 15 (FFTLTAYAV*PWTQK), representative of UGT1A4, that contains a tryptophan
residue, would normally be excluded based on selection criteria, yet the peptide produced
consistently linear standard curves (r2>0.97, data not shown) and acceptable C.V. values on
interday and intraday variability testing (Table S-1, S-2). Reproducible product ions could
not be obtained for peptide 16 (VTLGYTQGF*FETEHLLK) and peptide 17
(GHQVVVL*TLEVNMYIK) because the parent ions from these peptides were from the +3
to +5 charge states, making both MRM analysis and chromatography cumbersome and often
unresolvable. In addition, peptide 5, representing UGT1A3 (HVLGHTQL*YFETEHFLK),
could not be used. This peptide was quadruply charged as parent ion as a result of multiple
histidine residues within the sequence. Along with peptides 5, 16 and 17, peptide 10
(TYSTSYTL*EDLDR) was excluded from UGT analysis due to lack of specificity for a
particular isoform since its peptide sequence was shared by both UGT1A8 and UGT1A9.
Often the best peptides of those employed for UGT analysis contained single or multiple
proline residues that exhibit the well documented “proline effect” that is responsible for
favorable cleavage near proline sites under collision induced dissociation (CID) MS
conditions38. Based on our experience, optimal peptide selection is of the utmost importance
for accurate quantification of proteins digested to peptides. While some guidelines
recommend that peptides as large as 16 mer may be selected, it is often smaller peptides
between 8-10 mer in length containing proline and no reactive residues (C, M, W) that
perform better for high sensitivity MRM based peptide quantification7, 28, 34.
Initial analysis was performed with an extended gradient of 2-60 % B over 60 min. Assay
length (95 min run time) and lack of signal intensity resulted in several alterations, including
a higher starting % B, but this was again inadequate due to peak splitting and band
broadening with the stable isotope standards. Following further modification, a 5-55 % B
gradient over 30 min provided both the highest signal intensity and shortest run time on the
instrumentation. Peptides eluted between 17 and 32 min over five distinct time segments. To
maximize MRM collections, eight to sixteen transitions were monitored in each segment,
enabling quantification of all UGT1As within a single chromatographic run. Although the
LIT-TOF used could only monitor a maximum of 100 MRM transitions within a single
chromatographic run, this was sufficient to monitor the maximum 68 MRM transitions of
interest in this study.
With the exception of peptides 5, 14, 16, 17 and 18, all peptides generated calibration curves
that were linear for a range of recombinant microsomal protein. When the stable isotope
calibrants were incorporated, this represented a range of 1.0 to 140 pmol/mg protein.
Because determined concentration variability was <30 % between the peptide MRMs
monitored, MRM values for each UGT1A isoform were averaged to generate expression
datasets. For peptides with only one unique peptide, two MRM measurements were
averaged from the single peptide. The highest detected UGT concentration was 96.4 pmol/
mg protein of UGT1A9 within the kidney; however, even this concentration was well within
the linear range of the assay. Wang et al.35 demonstrated that some CYP isoforms are
expressed in much higher concentration than UGT enzymes (>300 pmol/mg protein),
indicating that the digested protein levels may need to be adjusted between assays to remain
within the linear range of some instruments.
Enzyme expression data generated for the liver, intestine and kidney generally agree with
previous reports for both mRNA expression and in vitro glucuronidation profiles1, 3, 39, 40.
Within the liver, UGTs 1A1 and 1A9 were consistently expressed at a higher level than 1A3,
1A4 and 1A6 (Table 2, , Figure 3). While there have been conflicting reports of the
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predominately extrahepatic UGTs 1A7, 1A8 and 1A10 being present in the liver, none of
these enzymes were detected in either pooled or individual HLMs33, 41, 42. Within the liver,
the highest variability in individual donor specimens was found with UGT1A1 and
UGT1A9 isoforms (Table 2), both of which have well documented polymorphisms1, 3, 29, 42.
Within the intestinal tract, expression of UGTs 1A1 and 1A6 was approximately 35 % of
expression seen in livers, which concurs with our previous investigation into these
isoforms25. Furthermore, previous studies by Wen et al40 with etoposide, a UGT1A1 and
1A8 probe substrate, indicated that the Vmax of etoposide glucuronidation rates in the
intestine was approximately 30 % of liver levels. While UGTs 1A1, 1A6 and 1A9 were
detected within the pooled intestinal digests, levels were appreciably lower than in the liver
microsomes. UGT1A8 was expressed at a higher level in the intestine than in the kidney.
Individual patient levels of UGT1A8 appeared highly variable within the intestine, yet there
have been few UGT1A8 polymorphisms reported with appreciable effects on
glucuronidation43. High variability was also seen between sample sets of the pooled human
intestinal microsomes and the individual specimen donors. UGT1A4 was not detected
within any of the pooled intestinal digests but was detected in each of the individual
specimens (Table 2). Individual patient variability, drug interactions or genetic
polymorphisms seen in UGT1A4 could be the source of the discrepancy45.
Expression levels within the kidney microsomes were much higher than in the intestine and
sometimes higher than seen in the liver. In particular, UGT1A9 was expressed at a level
nearly four fold that of the liver (81 pmol/mg protein, Figure 3). While mRNA and protein
correlation is often poor, recent reports characterizing UGT mRNA expression indicated
UGT1A9 was highly expressed within the human kidney 32, 39. However, it is important to
note that when making comparisons between mRNA assays and our UGT assay, one must
take into account the numerous polymorphisms within the UGT gene family that result in
high expression variability in the tissue within the population. Altered protein expression
affected by SNPs or other polymorphisms in human tissues could account for the low level
discrepancies in 1A3expression within the intestine and kidney for both the UGT assay and
mRNA values 32, 39 . Despite some differences in mRNA expression, UGT expression
within the kidney coincides with mycophenolic acid (MPA) glucuronidation levels that are
also three fold higher in the kidney compared to the liver and fifteen fold higher than those
seen in the intestinal tract 44. Not only were enzyme levels highest in the kidney for UGTs
1A4, 1A7, 1A9 and 1A10, but only UGTs 1A3 and 1A5 were not detected, making the
kidney a potentially important organ for clearance via glucuronidation in the body.
Conclusion
By combining the advantages of nanoLC coupled with the new LIT-TOF instrumentation,
we have developed and applied a method to detect eight of the nine active human UGT1A
isoforms within a single chromatographic assay. Our assay demonstrates acceptable
variability (<25 %) with comparable sensitivity relative to our earlier method performed
using older triple quadrupole (API 3000) instrumentation and regular bore LC25. The use of
nanoLC allowed for a dramatic reduction of protein needed for the assay without a loss of
sensitivity. Furthermore, we are now able to compare absolute expression levels of UGTs
within different tissues in humans that are comparable to previous reports of relative mRNA
expression measured in RT-PCR studies. The significant levels of UGT expression within
the kidney demonstrate that this organ could have a potentially important role in glucuronide
disposition within the body. Liver expression was generally higher than levels seen within
the intestine, but more UGT1A isoforms were detected in kidney compared with the liver.
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While the liver is seen as the primary organ involved in metabolite disposition, the
importance of other organ systems within the body should not be underestimated. The
emergence of novel targeted quantitative proteomic methods based upon LC-MS/MS will
allow the proliferation of protein expression studies, especially for the many proteins for
which specific antibodies have not been successfully raised. The ability to quantify specific
proteins within and between species without a reliance on antibodies opens many new
avenues of research into xenobiotic metabolism including such areas as protein-protein
interactions, enzyme regulation and induction/inhibition studies. These newly developed
analytical methods will significantly improve the ability to evaluate and interpret in vitro
and in vivo studies in drug development.
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LIT-TOF spectrum analysis of peptide 1 (Table 1-UGT1A1) following injection of 10 pmol
of peptide on nanoLC-MS/MS showing optimum product ions 557.3 (y4) and 753.4 (y6) for
use in MRM transitions.
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Representative extracted ion chromatograms showing peptide 1 (T78YPVPF*QR85), labeled
and unlabeled (A and B, respectively), from UGT1A1, eluting at 20.3 min, estimated as 22.7
pmol/mg protein, and peptide 4 (S103FLTAP*QTEYR113 ) (C and D, labeled and unlabeled,
respectively), from UGT1A6, estimated as 8.5 pmol/mg protein.
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Comparison of human UGT enzyme expression from five replicate measurements of digests
of pooled human liver, intestinal and kidney microsomes (HLM, HIM and HKM
respectively). Data are presented as mean values of each enzyme obtained from averages of
two MRMs from one or two peptides as detailed in Methods. Standard deviation bars are
shown. * UGT1A5 was not measured.
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